Medical Policy:

Aphexda (motixafortide) subcutaneous injection

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.403	February 18, 2025	December 18, 2023

Definitions

Aphexda is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Length of Authorization

Coverage will be provided for two doses only.

Dosing Limits [Medical Benefit]

- Aphexda 62mg single dose vial 2 vials per dose for two doses only
- Max Units per dose and over time: 124mg (2 vials) per dose up to two doses.

Guideline

I. Initial

1. **Multiple Myeloma.** Approve if the patient meets the following (A, B, C, **AND** D):
   A. Patient is ≥ 18 years of age; **AND**

B. Patient will not in combination with other CXCR4-antagonists (e.g., mavorixafor, plerixafor, etc.)
C. The agent is utilized for mobilization of hematopoietic stem cells for subsequent autologous transplantation; **AND**
D. Use is in combination with filgrastim; **AND**
Note: Examples of filgrastim products include Granix (tbo-filgrastim subcutaneous injection) and Neupogen (filgrastim subcutaneous injection and intravenous infusion), as well as related biosimilars.
E. Medication is prescribed by a hematologist and/or a stem cell transplant specialist physician.

II. Renewal
Coverage cannot be renewed.

Dosage/Administration

Indication	Dose
Peripheral mobilization of stem cells for autologous transplantation	Administer filgrastim 10 mcg/kg subcutaneously once daily for 4 days prior to the first dose of Aphexda and on each day prior to each apheresis. The recommended dosage of Aphexda is 1.25 mg/kg administered via slow (approximately 2 minutes) subcutaneous injection 10 to 14 hours prior to the initiation of the first apheresis (Day 5). • If cell collection goal was not achieved, another dose of filgrastim may be administered on Day 6 within 1 hour prior to the second apheresis. • If cell collection goal was still not achieved, a second dose of Aphexda can be administered 10 to 14 hours before a third apheresis (preceded by filgrastim) on Day 7, if necessary. – Monitor patients for one hour after administration.

Applicable Procedure Codes

Code	Description
J2277	Injection, Motixafortide, 0.25mg

Applicable NDCs

Code	Description
82737-0073-01	Aphexda 62 mg One single-dose vial

ICD-10 Diagnoses

Code	Description
Z52.011	Autologous donor, stem cells
Z52.091	Other blood donor, stem cells
Z94.84	Stem cells transplant status

Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	2/18/2025	Addition to initial criteria: of Patient will not in combination with other CXCR4-antagonists (e.g., mavorixafor, plerixafor, etc.)
EmblemHealth & ConnectiCare	12/18/2023	New Policy

References

1. Aphexda™ subcutaneous injection [prescribing information]. Waltham, MA and Modi'in, Israel: BioLineRx; September 2023.
2. The NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology (version 4.2023 – August 25, 2023). © 2023 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on December 11, 2023
3. Aphexda. Lexicomp [database online]. Waltham, MA, Available at https://online.lexi.com. Accessed December 11, 2023.
4. Aphexda. IPD Analytics. Available at: http://secure.ipdanalytics.com. Accessed on December 4, 2023
5. Aphexda IBM Micromedex® [database online]. Waltham, MA, 2023. BioLineRx USA Inc Health Analytics. Available at: https://www.micromedexsolutions.com. Updated September 26, 2023. Accessed December 11, 2023.
6. US Food & Drug Administration (FDA): Orphan Drug Designation Database. US Food & Drug Administration (FDA). Silver Spring, MD. 2022. Available from URL: https://www.acces... . As accessed December 11, 2023.